Brege Laura

Director Laura Brege sells 17,000 shares (52.0% of holdings) at $74.40 avg, reducing stake from 32,703 to 15,703 shares

Laura Brege, a director of Mirum Pharmaceuticals, executed two separate sales on 2025-09-11 totaling 17,000 shares for $1,264,868.43, reducing her holdings by 52.0%. The sales occurred at prices of $74.34 and $75.07, near the current price of $74.31 and within the 52-week range of $37.85–$77.69. Notably, Mirum reported revenue of $127,785,000.00 in its latest quarter with strong annual revenue growth of +80.8%, but the company remains unprofitable with net income of $-5,861,000.00 in its most recent quarter. This substantial reduction in the director's stake warrants examination of whether the sale reflects conviction about near-term valuation levels or operational performance, particularly given the company's growth trajectory offset by persistent losses.

Director Brege Laura bought 1,000 PCRX shares at $12.81 on 2024-08-16; 4 other insiders also bought within 14 days as stock down -54.8% over 90 days

Director Laura Brege purchased 1,000 shares at $12.81, increasing her position from 16,552 to 17,552 shares. This transaction is noteworthy in context: the stock has fallen -54.8% over the past 90 days and -27.8% in the past 30 days, trading at $13.98 versus a 52-week high of $37.88. Critically, a cluster pattern emerged with 4 other insiders also buying within the past 14 days, suggesting coordinated or simultaneous interest at depressed price levels. The company maintains modest fundamentals with $178.0M quarterly revenue and $18.9M net income, and trades at a P/E of 10.13 with a market cap of $644.9M. The convergence of multiple insider purchases during a sharp selloff merits investor attention.